Five-year survival and associated factors in women treated for cervical cancer at a reference hospital in the Brazilian Amazon

Abstract

Cervical cancer (CC) is the most common type of cancer in women and is the third leading cause of death in most developing countries, causing more than 288,000 deaths in women worldwide each year. The most favourable survival rate is in developed countries, since CC mortality has recently declined in those countries. The purpose of this study was to determine the survival rate and associated factors of CC patients at a reference hospital in the Amazon region. The patient sample included records of 339 patients with cervical cancer who had been hospitalized in Belém, Pará, Brazil from January 2005 to December 2010; the socioeconomic and clinical data were collected between June and September 2016. A survival rate of approximately 84% was observed, and it was found that disease stage (p <0.01), metastasis (p <0.01) and readmission (p <0.01) had significant influences on patient outcome. The impact of these factors on the general survival rate was higher in the Amazon region compared with other regions of Brazil, and the primary survival factors were associated with earlier stages of the disease. However, more national studies are needed on this subject. Our findings may contribute to the development of regional strategies for the prevention of cervical cancer, a reduction in its incidence and mortality rate, an increase in survival time and an improvement in the quality of life of these women.

Analysis of the effects of the age-period-birth cohort on cervical cancer mortality in the Brazilian Northeast

“…In addition to the low coverage and poor quality of screening programs, the PNCC presents difficulties associated with the referral of women with cervical cancer or their precursor lesions to treatment in specialized services (surgery, chemotherapy and radiotherapy) [56][57][58][59], correlating with the large proportion of women diagnosed in advanced stages of this disease (III/ IV). In Brazil, from 2006 to 2012, only 29% of women with CC were diagnosed at the early stage of the disease (in situ or stage IA carcinoma).…”

“…The presence of an advanced tumor (lymph node involvement and the presence of distant metastases) in the diagnosis represents the main factor associated with shorter five-year survival in women diagnosed with cervical cancer [56][57][58]. Women in group I (stages IA to IB) had a five-year survival of 92.3%, while women in group II (stages IIA to IVB) had a five-year survival of only 32.7% [58]. Women living in the Northeast were more likely to be diagnosed at an advanced stage than women living in the Southeast (OR = 1.32; 95% CI 1.25-1.40) [45].…”

<p>Effects of Nicotinamide on Cervical Cancer-Derived Fibroblasts: Evidence for Therapeutic Potential</p>

“…Cervical cancer patients have an overall five-year survival of 84% across all the stages. 2 However, the survival rate is further reduced to 17%, if cancer manages to metastasis to distant organs in the body, which emphasizes the importance of early diagnosis and treatment of cancer. 3 Unfortunately, drug resistance is inevitable in this cancer, which further makes it very difficult to contain and prevent metastasis.…”

The Effects of Preoperative Oral Carbohydrate on Frequency of T and NK Cells in Patients with Cervical Cancer Treated Using Neoadjuvant Chemotherapy and Surgery: A Prospective Cohort Study

“…(1) female aged 18-60 years; (2) American Society of Anesthesiologists (ASA) level I or II; (3) cervical squamous cell carcinoma confirmed by cervical biopsy and pathology; (4) no distant metastasis observed on computed tomography (CT); (5) CT, magnetic resonance imaging (MRI), positron emission tomography (PE), and/or B-ultrasound and gynecologic examinations indicated stage IB1 or IIA1 disease with a cervical tumor mass of 2-4 cm (non-NAC group) or stage IB2 or IIA2 disease with a cervical tumor mass > 4 cm (NAC group); (6) the planned surgery was laparoscopically assisted RH with bilateral salpingo-oophorectomy and PLND; and (7) the planned chemotherapy regimen (NAC groups) was two courses of paclitaxel and cisplatin, with an interval of 4 weeks between the second course and surgery. The exclusion criteria were as follows: (1) previous chemotherapy (for patients in the NAC groups); (2) dysfunction of gastric emptying; (3) diabetes mellitus or impaired glucose tolerance; (4) body mass index ðBMIÞ > 32 or <18.5 kg/m 2 ; (5) multiple cervical tumors; (6) tumor recurrence; and (7) functional disorders of the respiratory, circulatory, immune, nervous, or urinary system or any other organs.…”

“…Therapies for cervical cancer include radical hysterectomy, chemotherapy, radiotherapy, and concurrent chemoradiotherapy [3]. However, the recurrence rate is 10%-50%, and the 5-year survival is around 65%, although this varies with the disease stage [4].…”